New baseline biomarkers in Bionomics cancer trial
Bionomics (ASX:BNO) has revealed new data from the DisrupTOR-1 trial of its anticancer candidate BNC105 in patients with metastatic renal cancer. The data, which was presented at the ASCO Genitourinary Cancers Symposium in Florida last week, identifies Ferritin and IL-8 as two baseline biomarkers that correlate with an improved progression-free survival (PFS) in patients.
Elevated baseline Ferritin and lower baseline IL-8 were associated with improved PFS, with 89% of patients expressing such conditions found to be progression-free at six months. Bionomics CEO and Managing Director Dr Deborah Rathjen noted, “This is a compelling improvement compared to the 34% PFS observed at six months in the unselected population.”
Dr Sumanta Pal, who presented the data, said the findings suggest “baseline levels of Ferritin and IL-8 may predict an excellent clinical outcome with the combination of [cancer medication] Afinitor with BNC105”. A prospective biomarker-driven study examining combined Afinitor and BNC105 treatment of renal cancer patients selected by baseline IL-8 and Ferritin is now in development.
Bionomics has separately announced that Dr Rathjen will present a corporate overview of the company at two upcoming conferences: ASX Spotlight New York on 5 March in New York and the 27th Annual ROTH Conference on 10 March in California. She appeared today at the Cowen & Co 35th Annual Health Care Conference in Massachusetts.
This week also marks Bionomics’ entry into the OTCQX marketplace in the US, in a move which provides US investors with the ability to trade the company’s ordinary shares in US dollars during US market hours. Dr Rathjen said, “We have seen growing interest from US investors in Bionomics joining the OTCQX marketplace - a logical move that will provide new opportunities for the company.”
Bionomics (ASX:BNO) shares were trading 1.01% higher at $0.50 as of around 2 pm on Tuesday
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
